Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019
April 08, 2020 at 02:33 pm IST
Share
Nanjing Hicin Pharmaceutical Co., Ltd. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced sales was CNY 924.537 million compared to CNY 711.907 million a year ago. Operating income was CNY 114.266 million compared to CNY 96.516 million a year ago. Net income was CNY 97.258 million compared to CNY 83.223 million a year ago. Basic earnings per share from continuing operations was CNY 0.8105 compared to CNY 0.6935 a year ago.
Nanjing Hicin Pharmaceutical Co Ltd is a pharmaceutical company engaged in research, development and production of chemical preparations, active pharmaceutical ingredients and intermediates. The Company's primary products are torsemide for injection, tigecycline for injection, cefoxitin sodium for injection, cefotiam for injection and omeprazole sodium for injection. The torsemide for injection is a loop diuretic. The tigecycline for injection is an intravenous administrated glycyrrhizin antibiotic for the treatment of complex skin and skin structure infections or complex intra-abdominal infections. The cefoxitin sodium for injection is a cephalosporin antibiotic used for the treatment of respiratory, urinary and gastrointestinal infections. Its products cover a range of therapeutic areas, including diuresis, cardiovascular, anti-infection, digestive system, immune regulation, hypoglycemic and orthopedics.
NANJING HICIN PHARMACEUTICAL CO., LTD. 
